Statin therapy for Takayasu Arteritis

First marketed>30  years ago, statins quickly became a therapeutic cornerstone in coronary artery disease primary and secondary prevention. Statins exert their low density lipoprotein-cholesterol lowering effect through inhibition of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzy me in the L-mevalonate pathway. During the last several years, knowledge on statins pharmacologic properties has constantly expanded, unveiling a surprisingly wide array of metabolic interactions which accounts, at least in part, for their complex biologic effects in vivo [1].
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research